

**[334] SMARTZYME BIOPHARMA: BETTER CONTINUOUS GLUCOSE MONITORS WITH A NEXT-GENERATION GLUCOSE-SENSING ENZYME**

**Christopher Shepard<sup>1</sup>, Adely Levy<sup>2</sup>, Igor Hayfetz<sup>2</sup>, Dotan Amar<sup>2, 1</sup> 601 Lexington Ave, 54th Floor, <sup>2</sup> Smartzyme Biopharma**

- **Investment Rational**  
SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing and more affordable continuous glucose monitoring for people with diabetes. SmartZyme is an OrbiMed Advisors portfolio company with a management team and Board that has a track record of successful exits in the medical device and diabetes space.
- **Business Strategy**  
The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingerstick-calibration for the best quality of life.
- **Core Technology**  
SmartZyme has engineered a novel glucose-sensing enzyme that can be incorporated into existing continuous glucose monitors to reduce the cost of the device by 90%. The reduction in cost is a result of the enzyme's ability to transfer electrons directly to the electrode without the use of electron mediators that exorbitantly add to the manufacturing cost and complexity of current devices.
- **Product Profile/Pipeline**  
SmartZyme is currently validating the technology in multi-day animal studies. The studies demonstrate superior accuracy in the lowest ranges of glucose-sensing compared to on-market devices. SmartZyme closed a B-1 round in early 2018 to accelerate our CGM to clinical trials and scale-up manufacturing of the enzyme.
- **What's Next?**  
SmartZyme plans to continue animal validation testing to accelerate the company into the clinic.